Chengdu TIDE officially submits commitment letter to the Science Based Targets initiative (SBTi)

Recently, Chengdu Huaxia Drug Development Co., Ltd. (hereinafter referred to as "Chengdu Huaxia," stock code: 688222.SH), a listed company on the Shanghai Stock Exchange, officially submitted a commitment letter to the Science Based Targets initiative (SBTi), pledging to set near-term science-based carbon reduction targets aligned with SBTi standards within two years. Chengdu Huaxia plans to implement a series of emission reduction measures to reduce greenhouse gas emissions across its entire value chain to levels consistent with the 1.5°C climate goal outlined in the Paris Agreement. This marks substantial progress in Chengdu Huaxia's efforts toward corporate sustainability and ESG (Environmental, Social, and Governance) strategy.

The Science Based Targets initiative (SBTi) was originally launched by CDP (formerly Carbon Disclosure Project), the United Nations Global Compact (UNGC), We Mean Business Coalition, World Resources Institute (WRI), and World Wildlife Fund (WWF). It aims to help companies set science-based carbon reduction targets in line with the Paris Agreement. To date, over 10,000 companies from more than 100 countries and regions worldwide have submitted SBTi commitments.

"We are delighted to take this crucial step forward by joining SBTi, a global alliance of corporate climate action leaders," said Dr. Jin Li, Chairman and CEO of Chengdu Huaxia. "Setting science-based carbon targets is not only a concrete demonstration of our corporate social responsibility but also a tangible action to create a healthier planet for future generations. This aligns closely with Chengdu Huaxia's mission of improving human health through innovative technologies."

This commitment reflects Chengdu Huaxia's determination to integrate sustainability into its long-term development strategy. As an innovation-driven biotechnology enterprise, Chengdu Huaxia deeply recognizes the urgency of addressing climate change and its profound impact on global health and well-being. By planning a scientifically grounded emission reduction pathway, Chengdu Huaxia aims not only to minimize the environmental impact of its own operations but also to drive the entire industry supply chain toward green and low-carbon transformation.

About Chengdu Huaxia

Chengdu Huaxia Drug Development Co., Ltd. (Shanghai Stock Exchange stock code: 688222.SH, stock name: Chengdu Huaxia) is committed to building a world-leading innovative biopharmaceutical company. Headquartered in Chengdu, China, it has subsidiaries in Cambridge, UK, and Houston, USA. The company focuses on the discovery and optimization of small molecule and nucleic acid new drugs, and has established an internationally leading DNA-encoded compound library (DEL) platform. It has further developed core technology platforms including fragment-based and structure-based drug design (FBDD/SBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation (TPD). Additionally, the company is building a DEL+AI+automated DMTA (Design-Make-Test-Analyze) molecular optimization capability platform to accelerate the discovery and optimization of preclinical candidate drugs. Through diversified business models—including new drug R&D services, licensing out of pipeline assets at various stages, and future drug commercialization—Chengdu Huaxia has established collaborations with hundreds of pharmaceutical companies, biotech firms, chemical companies, foundations, and research institutions globally. Currently, the company has multiple internal new drug programs at various clinical and preclinical stages.